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To use diﬀusion basis spectrum imaging (DBSI) to assess how damage to normal-appearing
white matter (NAWM) in the corpus callosum (CC) inﬂuences neurologic impairment in
people with MS (pwMS).
Methods
Using standard MRI, the primary pathologies in MS of axonal injury/loss, demyelination, and
inﬂammation are not diﬀerentiated well. DBSI has been shown in animal models, phantoms,
and in biopsied and autopsied human CNS tissues to distinguish these pathologies. Fifty-ﬁve
pwMS (22 relapsing-remitting, 17 primary progressive, and 16 secondary progressive) and 13
healthy subjects underwent DBSI analyses of NAWM of the CC, the main WM tract con-
necting the cerebral hemispheres. Tract-based spatial statistics were used to minimize mis-
alignment. Results were correlated with scores from a battery of clinical tests focused on deﬁcits
typical of MS.
Results
Normal-appearing CC in pwMS showed reduced ﬁber fraction and increased nonrestricted
isotropic fraction, with the most extensive abnormalities in secondary progressive MS (SPMS).
Reduced DBSI-derived ﬁber fraction and increased DBSI-derived nonrestricted isotropic
fraction of the CC correlated with worse cognitive scores in pwMS. Increased nonrestricted
isotropic fraction in the body of the CC correlated with impaired hand function in the SPMS
cohort.
Conclusions
DBSI ﬁber fraction and nonrestricted isotropic fraction were the most useful markers of injury
in the NAWM CC. These 2 DBSI measures reﬂect axon loss in animal models. Because of its
ability to reveal axonal loss, as well as demyelination, DBSI may be a useful outcome measure
for trials of CNS reparative treatments.
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MS is a common inﬂammatory CNS disorder, aﬀecting over
600,000 people in the United States.1 Irreversible axonal in-
jury and loss are believed to be the main causes of permanent
neurologic impairments in MS. Yet, standard MRI does not
measure axonal loss.2 To address the need for a noninvasive
method to detect and discriminate axonal loss from other
pathologies, such as inﬂammation and demyelination, we
developed diﬀusion basis spectrum imaging (DBSI) to accu-
rately detect and distinguish components of white matter
(WM) pathologies in MS.3 Using preclinical models, we
previously showed that DBSI quantitatively assessed apparent
axonal density (anisotropic diﬀusion tensor fraction), appar-
ent cellularity (restricted isotropic diﬀusion tensor fraction),
and edema and tissue loss (nonrestricted isotropic diﬀusion
tensor fraction).3–5
We hypothesized that DBSI metrics reﬂecting axon damage in
normal-appearing WM (NAWM) would correlate with neu-
rologic impairment in people with MS (pwMS). The corpus
callosum (CC) is a major WM structure connecting the 2
cerebral hemispheres that is frequently aﬀected by MS pa-
thology.6 We used DBSI and tract-based spatial statistics
(TBSS), a widely used approach to avoid registration errors,7
to assess NAWM of the CC in pwMS and healthy controls
(HCs). We compared DBSI analysis on a TBSSWM skeleton
between cohorts representing the 3 main clinical subtypes of
MS.8 DBSI ﬁndings at the voxel level and region of interest
level were examined for correlations with results of stan-
dardized tests of cognition and physical function.
Methods
Human subjects
Procedures were approved by the Institutional Review Board
of Washington University. Each participant provided written
informed consent. Thirteen HC subjects and 55 pwMS with
clinical subtypes conﬁrmed by 2 investigators, including 22
with relapsing-remitting MS (RRMS), 16 with secondary
progressive MS (SPMS), and 17 with primary progressive MS
(PPMS), were enrolled between 2014 and 2017. Knowing
that the subjects with SPMS and PPMS would be older, we
purposefully recruited older subjects with RRMS so that the
MS clinical subtype cohorts would be of similar ages to reduce
the confounding eﬀect of age on MRI ﬁndings.
Clinical evaluation
All subjects, including HCs, completed a battery of clinical
tests within 5 days of imaging, administered by trained
examiners who were blinded to DBSI ﬁndings. Tests in-
cluded the Expanded Disability Status Scale (EDSS),
a global composite of neurologic function with particular
emphasis on gait and considered as a “gold standard” in
MS, and the Multiple Sclerosis Functional Composite
(MSFC, comprising 9-Hole Peg Test [of upper extremity
function], Timed 25-Foot Walk [test of gait and leg
function], and 3- and 2-second Paced Auditory Serial
Addition Test [PASAT2, PASAT3, test of attention,
working memory, and auditory processing speed]). Be-
cause more than 50% of pwMS are impaired in the cog-
nitive domains of processing speed, and learning and
memory,9 additional tests of cognition were performed:
the Symbol Digit Modalities Test (to assess attention and
visuospatial processing speed) and the Brief Visuospatial
Memory Test-Revised, total and delayed recall (to assess
visuospatial memory and processing speed), and Selective
Reminding Test total and delayed recall (to assess verbal
memory, new learning, and recall). Published normative
results were used to calculate z-scores.9
MRI acquisition
Subjects underwent MRI at 3.0T (Trio; Siemens, Erlangen,
Germany) using a 32-channel head coil. T1 weighted
magnetization-prepared rapid gradient-echo (MPRAGE) scan
with an isotropic 1 mm3 resolution was used for identiﬁcation of
structural landmarks and for coregistration (repetition time
[TR] = 2,400ms, echo time [TE] = 3.16ms, inversion time [TI]
= 1,000 ms, matrix = 256 × 224, ﬁeld of view [FOV] = 256 ×
224 mm2, resolution = 1 × 1 × 1 mm3). A ﬂuid-attenuated
inversion recovery (FLAIR) scanwas acquired to quantify visible
WM lesions (TR = 7,500 ms, TI = 2,500 ms, TE = 210 ms, TI =
2,500ms,matrix = 256 × 256, FOV= 256 × 256mm2, resolution
= 1 × 1 × 1 mm3). Diﬀusion-weighted images (DWIs) were
collected with a 99-direction multi-b-value diﬀusion encoding
scheme by single-shot spin-echo echo-planar imaging sequence
with the following key parameters: voxel size = 2 × 2 × 2 mm3;
maximum b value = 1,500 seconds/mm2; acquisition time = 16
minutes. Two transverse non–diﬀusion-weighted images (b =
0 s/mm2) with opposite polarity of the phase encoding direction
(AP and PA) were acquired for image processing.
Glossary
AD = axial diﬀusivity; BBB = blood-brain barrier; BVMT-R = Brief Visuospatial Memory Test–Revised;CC = corpus callosum;
DBSI = diﬀusion basis spectrum imaging; dMRI = diﬀusion MRI; DTI = diﬀusion tensor imaging; DWI = diﬀusion-weighted
image; EDSS = Expanded Disability Status Scale; FA = fractional anisotropy; FLAIR = ﬂuid-attenuated inversion recovery; Fr =
fraction; FSL = Functional MRI of the Brain Software Library; FTW = foot walk;HC = healthy control.HPT = Hole Peg Test;
IQR = interquartile range; MPRAGE = magnetization-prepared rapid gradient-echo sequence; MSFC = MS Functional
Composite; NAWM = normal-appearing white matter; PPMS = primary progressive MS; pwMS = people with MS; RD = radial
diﬀusivity; RRMS = relapsing-remitting MS; SDMT = Symbol Digit Modalities Test; SPMS = secondary progressive MS; SRT =
Selective Reminding Test;TBSS = tract-based spatial statistics;TFCE = threshold-free cluster enhancement;WM = white matter.
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Image processing and lesion mapping
DWIs were preprocessed to minimize motion and susceptibility
artifact due to nonzero oﬀ-resonance ﬁelds. The FSL-based
“TOPUP” tool, which estimates the susceptibility-induced oﬀ-
resonance ﬁeld from pairs of images, with reversed phase-
encode blips and distortions going in opposite directions,10 and
the Functional MRI of the Brain Software Library (FSL)-based
“EDDY” tool, which corrects image distortions by combining
the correction for susceptibility and eddy currents/movements,
were used. Both B0 and FLAIR images were aligned to
MPRAGE using an aﬃne registration. WM lesions were man-
ually traced on FLAIR. Subsequently, each lesion mask was
nonlinearly transformed onto a common WM skeleton and
lesions removed to reveal NAWM before statistical analysis.
DBSI
DBSI metric maps were estimated on the preprocessed DW
images using the in-house software developed using MAT-
LAB. DBSI models diﬀusion-weighted MRI signals as a linear
combination of multiple tensors describing both the discrete
anisotropic axonal ﬁbers and an isotropic diﬀusion spectrum
encompassing the full range of diﬀusivities,3 equation 1.
Sk = +
NAniso
i = 1 fie
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where Sk and jbk
⇀
j are the normalized signal and b value of the
kth diﬀusion gradient, NAniso is the number of anisotropic
tensors, ψik is the angle between the k
th diﬀusion gradient and
the principal direction of the ith anisotropic tensor, λjji and λ’i
are the axial diﬀusivity (AD) and radial diﬀusivity (RD) of the
ith anisotropic tensor, fi is the signal intensity fraction for the
ith anisotropic tensor, and a and b are the low and high dif-
fusivity limits for the isotropic diﬀusion spectrum f(D). The an-
isotropic diﬀusion component describes water molecules inside
and immediately outside myelinated or nonmyelinated axons.
DBSI-derived anisotropic signal intensity fractions (fi, i.e., ﬁber
fraction) can also be deﬁned as apparent axonal density in WM.
DBSI-derived AD and RD retain the pathologic speciﬁcity for
axonal injury and demyelination as previously proposed but with
fewer confounds from coexisting MS pathologies using DBSI.
Cellular and axonal packing plays a crucial role in extracellular and
extra-axonal diﬀusion characteristics. Less restricted or non-
restricted isotropic diﬀusion components represent water mole-
cules in less densely packed environments, such as areas of tissue
disintegration or edema or nonrestricted water within CSF.3,11,12
The DBSI-derived “restricted” isotropic diﬀusion fraction (ADC
≤0.3 μm2/ms) has been shown to reﬂect cellularity.3
Quantification of dMRI metrics on
WM skeleton
Whole-brain WM, voxel-wise statistical analysis of the images
was performed in blinded fashion on a commonWM skeleton
created using TBSS with the following steps.7 First, fractional
anisotropy (FA)maps were computed for each subject. Next, all
FAmaps from all subjects were aligned to standard-space image
(JHU-ICBM-FA-1 mm in Montreal Neurological Institute 152
space) using the FSL nonlinear image registration tool
FNIRT.13 The aligned FAmaps were then averaged to produce
a group mean image, thus generating an FA skeleton to high-
light the tracts common to the entire group. For each subject, an
FA threshold of 0.2 was used before projecting the aligned FA
map onto this skeleton. For subjects with MS, lesions were
manually demarcated on anatomical MRI and then excluded
before any statistical analysis. Resulting skeletonized FA maps
became the WM skeletons for subsequent analyses comparing
subtypes. All DBSI metrics were projected onto this WM
skeleton for voxel-based and for region-based statistical analyses.
The proportions of the CC that were signiﬁcantly diﬀerent
from the HC group were calculated by equation 2 and in-
dicated in ﬁgure 1.




Two types of analyses, voxel-level and region-level analyses,
were performed on the WM skeleton of the CC.
Voxel-based group comparison
Nonparametric permutation tests were used for voxel-wise
statistical analysis of the skeletons between HC and pwMS.7
The threshold-free cluster enhancement (TFCE) method was
applied to the statistical maps to enhance cluster-like structures
within the images and produce output images in which the
voxel-wise values represent the amount of cluster-like local
spatial support.14 This combination of permutation testing and
TFCEproduced a “smooth” (i.e., continuous)map of corrected
p values, 1 per voxel, that took into account spatial dependency
in the data. The signiﬁcance level was set at p≤ 0.05 after family-
wise error correction for multiple comparisons. The statistical
analyses were performed using the FSL tool RANDOMIZE.15
Region-based analyses
Median values of diﬀusion metrics within each region, in-
cluding the whole CC and its subregions, were compared
among patient subtypes. Subregions of the CC (splenium,
body, and genu) were based on the WM parcellations deﬁned
in ICBM-DTI-81 WM labels.16 Kruskal-Wallis one-way
nonparametric analysis of variance was used to test for any
diﬀerences between MS subtypes. A post hoc nonparametric
test using the Fisher least signiﬁcant diﬀerence method with
Holm-Bonferroni correction indicated the existence of sig-
niﬁcant diﬀerences between subtypes. The statistical analyses
were performed using software R.
Correlations of median regional DBSI values with clinical test
scores and subtypes were assessed using Spearman rank
correlation analysis. The signiﬁcance level was set at p ≤ 0.05
after Benjamini-Hochberg correction for multiple
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comparisons. Individual participants were considered as in-
dependent. HCs were excluded from analyses of dMRI cor-
relations with clinical tests. The statistical analyses were
performed using software R.
Data availability
Anonymized data will be shared upon reasonable request.
Results
Clinical characteristics
The HC (n = 13), RRMS (n = 22), PPMS (n = 17), and SPMS
(n = 16) subjects were similar in age (table 1). As expected, the
RRMS cohort performed better on neurologic tests than sub-
jects with PPMS, who performed better than subjects with
SPMS on motor and cognitive tests (table 1).17,18
Voxel-based assessments of NAWM in CC using
DBSI metrics
DBSI-derived ﬁber fraction (indicator of apparent axonal den-
sity) was lower in a signiﬁcantly larger percentage of voxels in the
normal-appearing CC among all clinical MS subtypes, relative to
HC, with variable spatial distributions. Overall, the median ﬁber
fraction of the CC inHC subjects was 0.67 (table 2). RRMS and
PPMS each had a slightly lower median overall ﬁber fraction
(0.63 and 0.63, respectively) compared with HC (table 2).
Subjects with SPMS had the lowest median ﬁber fraction of 0.57
(table 2). In addition, the spatial extent of reduced DBSI ﬁber
fraction in the normal-appearing CC varied, with 75% of the
normal-appearing CC being reduced in the SPMS cohort, 50%
in the PPMS cohort, and 3% in the RRMS cohort (ﬁgure 1).
DBSI-derived nonrestricted isotropic fraction (indicator of
tissue loss or edema) was signiﬁcantly higher in the vast
majority of voxels in the normal-appearing CC of all 3 clinical
subtype cohorts compared with HC (78%, 77%, and 98% for
RRMS, PPMS, and SPMS subtypes, respectively, ﬁgure 1).
Compared with HC, DBSI-derived restricted fraction (in-
dicator of apparent cellularity) was lower in a signiﬁcantly
larger percentage of voxels of the normal-appearing CC in
SPMS but not in RRMS or PPMS.
DBSI-derived FA (of residual ﬁber tracts) was reduced
compared with HC in the normal-appearing CC, with this
reduction encompassing variable proportions of the CC
depending on the MS subtype (31%, 15%, and 45% in RRMS,
PPMS, and SPMS, respectively). The spatial extent of voxels
with reductions in FA were consistent with increased DBSI-
derived RD covered 43%, 26%, and 47% of the normal-
appearing CC in RRMS, PPMS, and SPMS, respectively
(ﬁgure 1). No statistically signiﬁcant changes in DBSI-AD
were observed in the normal-appearing CC in any of the MS
subtypes (table 2).
Region-based DBSI metrics of the whole CC
The DBSI-derived metrics from the whole CC were
extracted. The median values for the CC were compared
among the MS clinical subgroups and to the values of HC
(ﬁgure 2). Consistent with voxel-based analyses, the SPMS
group was notable for having the most reduced ﬁber fraction
and the most increased nonrestricted isotropic fraction of
the MS subgroups.
DBSImetricsof thenormal-appearingCCcorrelate
with cognitive andmotor test scores in MS
Reduced DBSI ﬁber fraction correlated with worse cognitive
test scores (ﬁgure 3). DBSI-derived nonrestricted isotropic
fraction correlated negatively with cognitive test scores and
Figure 1 TBSS-based DBSI of normal-appearing corpus callosum revealed widespread abnormalities in fiber fraction,
nonrestricted fraction, fractional anisotropy, and radial diffusivity compared with healthy controls
DBSI metrics in the three clinical
subgroups of RRMS, PPMS, and SPMS
were compared with healthy controls
(HCs). Regions in red or blue repre-
sent regions with a significant in-
crease or decrease in that diffusion
metric in pwMS compared with HC,
respectively. The proportion of the
CC volumes that were significantly
different from the HC group is in-
dicated at the upper left corner of
each map. In the figures, the TBSS
skeleton was thickened for better
visibility. CC = corpus callosum; DBSI
= diffusion basis spectrum imaging;
PPMS = primary progressive MS;
pwMS = people with MS; RRMS = re-
lapsing-remitting MS; SPMS = sec-
ondary progressive MS; TBSI = tract-
based spatial statistics.
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with MSFC. Reduced isotropic restricted fraction had modest
correlations with worse scores on some cognitive tests. DBSI-
derived RD, AD, and FA showed minimal or no correlations
with any clinical test results (ﬁgure 3). DBSI parameters from
all subregions of the CC revealed correlations with cognitive
test scores, but not withmeasures of physical function (ﬁgure 3,
B–D). The only correlation between EDSS and any of the
DBSI metrics was with the nonrestricted isotropic fraction and
only in the SPMS group (r = −0.7, p < 0.01, data not shown).
Discussion
MRI studies have historically been very useful for the non-
invasive diagnosis of MS and to better understand the changes
over time in this chronic disease. MRI has been increasingly
used to assess the relationship between the distribution and
extent of pathology in the MS CNS and neurologic impair-
ment. However, correlations of T2-weighted brain MRI ab-
normalities with neurologic impairment in MS are weak.19 At
least part of this lack of correlation is due to the nonspeciﬁc
nature of abnormalities seen on standard MRI modalities.19
This is especially true in progressive MS, where CNS in-
ﬂammation becomes dissociated from BBB damage such that
gadolinium enhancement is far less useful to detect it.20,21
In this study, the main goal was to use DBSI, which is path-
ologically more speciﬁc than standard MRI, to help un-
derstand how damage to NAWM in the CC inﬂuences
neurologic disability in MS. Subjects of each of the 3 main
clinical subtypes were recruited to be of similar ages so that
Table 1 Clinical and test characteristics of HCs and the 3 cohorts of pwMS
HC (n = 13) RRMS (n = 22) PPMS (n = 17) SPMS (n = 16)
Sex (M/F) 7/6 7/15 5/12 3/13
Age 50.8 ± 12.4 53.0 ± 8.3 54.2 ± 10.7 56.7 ± 7.5
EDSS score 0 (0 to 0) 2.75 (2.00 to 3.38) 6 (4.50 to 6.50) 6 (5.25 to 6.50)
MSFC 0.61 (0.33 to 0.67) 0.44 (−0.12, 0.53) −0.39 (−1.04 to 0.09) −0.35 (−0.67 to −0.20)
PASAT3 0.29 (−0.15 to 0.52) 0.18 (−1.04 to 0.57) −0.28 (−1.19 to 0.34) −0.99 (−1.91 to 0.08)
PASAT2 −0.12 (−0.96 to 0.36) −0.38 (−1.59 to 0.78) −0.54 (−0.91 to 0.78) −1.27 (−1.85 to −0.75)
9HPT 0.67 (0.26 to 1.01) 0.15 (−0.13 to 0.47) −0.6 (−2.13 to 0.14) −0.75 (−1.21 to −0.22)
25FTW 0.49 (0.43 to 0.50) 0.45 (0.38 to 0.49) −0.09 (−0.35 to 0.11) −0.12 (−0.67 to 0.09)
SDMT 0.18 (−0.38.0.55) −0.9 (−1.36,-0.13) −1.04 (−2.07,-0.66) −2.02 (−2.74,-1.20)
BVMTR Tot 0.14 (−0.38 to 1.00) 0.05 (−0.64 to 0.66) −0.55 (−2.10 to −0.21) −0.98 (−2.28 to −0.38)
BVMTR Del 1.12 (−0.06 to 1.12) 0.53 (−0.65 to 0.53) −0.06 (−0.65 to 0.53) −1.24 (−3.15 to −0.65)
SRT Tot −0.48 (−1.44 to 0.62) −0.27 (−1.37 to 0.45) −0.89 (−2.12 to −0.34) −1.51 (−2.88 to −0.68)
SRT Del −1.14 (−2.10 to 0.29) −0.19 (−0.67 to 0.76) −0.67 (−2.10 to −0.19) −1.14 (−2.69 to −0.67)
Abbreviations: BVMTR = Brief Visuospatial Memory Test–Revised; EDSS = Expanded Disability Status Scale; FW = foot walk; HC = healthy control; HPT = Hole
Peg Test; MSFC = Multiple Sclerosis Functional Composite; PASAT = paced auditory serial addition test; PPMS = primary progressive MS; RRMS = relapsing-
remitting MS; SDMT = Symbol Digit Modalities Test; SPMS = secondary progressive MS; SRT = Selective Reminding Test.
Table 2 DBSI metrics within normal-appearing corpus callosum suggest axonal loss in patients with MS
HC (n = 13) RRMS (n = 22) PPMS (n = 17) SPMS (n = 16)
Fiber fraction 0.67 (0.60–0.69) 0.63 (0.59–0.70) 0.63 (0.57–0.66) 0.57 (0.49–0.67)
Restricted fraction 0.19 (0.17–0.20) 0.18 (0.16–0.19) 0.18 (0.15–0.22) 0.14 (0.12–0.16)
Nonrestricted fraction 0.12 (0.11–0.19) 0.19 (0.13–0.22) 0.16 (0.14–0.27) 0.26 (0.20–0.38)
DBSI FA 0.84 (0.83–0.87) 0.84 (0.81–0.86) 0.85 (0.82–0.87) 0.84 (0.83–0.87)
DBSI AD 1.96 (1.93–2.04) 2.04 (1.94–2.17) 1.99 (1.91–2.10) 2.06 (1.89–2.12)
DBSI RD 0.27 (0.25–0.30) 0.30 (0.26–0.37) 0.26 (0.24–0.31) 0.29 (0.24–0.33)
Abbreviations: AD = axial diffusivity; HC = healthy control; FA = fractional anisotropy; PPMS = primary progressiveMS; RD = radial diffusivity; RRMS = relapsing-
remitting MS; SPMS = secondary progressive MS.
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age-related pathologic ﬁndings would not be a confounding
factor. Patients with SPMS have more damage and less
remyelination and a greater brain lesion load compared with
patients with PPMS.22 People with RRMS are considered to
have the least axon loss, although neuropathologic conﬁr-
mation of this is sparse.23 The motor and cognitive test results
on our 3 patient cohorts reﬂected the expected hierarchy, with
subjects with SPMS performing worst, subjects with RRMS
performing best, and subjects with PPMS scoring in between
on the tests. We had hypothesized that axon damage in
NAWM, as detected by DBSI, would correlate with worse
scores on clinical tests of functions most often impaired in
pwMS. We found that reduced ﬁber fraction and increased
nonrestricted isotropic fraction correlated with cognitive
dysfunction and, to a far lesser extent, motor impairment. As
the ﬁber fraction reﬂects the apparent axonal density, and the
nonrestricted isotropic fraction is increased in regions of axon
ﬁber loss, the DBSI results supported our hypothesis. The
results indicated abnormalities in the NAWM of the CC in
pwMS suggesting loss of axons and also reﬂected the expected
hierarchy of severity among MS subtypes.
As MS treatments become greater in number and as the ﬁeld
moves toward reparative therapies, it is increasingly important
to elucidate the presence of preserved but demyelinated axons
to identify those pwMS who can best respond to potential
remyelinating therapies. Increased DBSI RD, reﬂecting de-
myelination of surviving axons, suggested that 26–47% of
NAWM of the CC in our MS cohort was demyelinated. En-
rollment of subjects with much demyelination and relative
axon sparing, as could be shown by DBSI metrics, would
enhance the ability to detect eﬃcacy in future trials of putative
remyelinating agents. Identiﬁcation of those who would
beneﬁt most from remyelination treatments might be further
improved by application of DBSI to other major WM tracts
beyond the CC, such as the internal capsules, cerebral
peduncles, and centrum semiovale regions, which we plan to
do in future studies.
DTI has been used previously to investigate pathologic
changes in the NAWM.24,25 However, DTI ﬁndings are
confounded by coexisting pathologies, making it pathologi-
cally less speciﬁc than DBSI.12 DTI works better when
studying strongly coherent WM tracts, such as mouse models
of MS and human optic neuritis. Studying these tracts, re-
duced AD determined by DTI was associated with patho-
logically veriﬁed axon injury in mice and worse outcomes in
humans.26,27
In the present study, we focused on the normal-appearing CC.
We assessed not only the degree of alteration of each DBSI
metric but also the volume of abnormal tissue within the non-
lesioned CC. The volume of abnormal tissue (compared with
a healthy cohort) within the normal-appearing CC reached
77%–98% for nonrestricted isotropic fraction in all 3 clinical
subtypes. These results likely reﬂect the well-known ﬁnding that
in pwMS, NAWM is often not normal.30 Notably, reduced axon
density in the normal-appearing CC has been shown by several
groups usingMR spectroscopy in living people with RRMS and
progressive MS.28 In the present studies, decreased DBSI ﬁber
Figure 2 Comparisons of DBSI parameters within normal-appearing CC among HC and MS clinical subtypes
The horizontal line within each box
indicates themedian, thedot indicates
mean, and the box encompasses the
IQR between Q1 (25th percentile) and
Q3 (75th percentile). Whiskers of the
boxes are defined as Q1 − 1.5 × IQR or
Q3 + 1.5 × IQR. Group comparisons
performed using Kruskal-Wallis one-
way nonparametric ANOVA and post
hoc nonparametric tests were com-
pared using the Fisher least significant
difference (LSD) method. p values
were adjusted using Holm-Bonferroni
correction for multiple comparisons.
*p < 0.05, **p < 0.01, ***p < 0.001.
ANOVA = analysis of variance; CC =
corpus callosum; DBSI = diffusion ba-
sis spectrum imaging; HC = healthy
control.
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fraction (putative marker of apparent axonal density, ﬁgure 1)
was seen most extensively in SPMS, followed by PPMS then
RRMS, consistent with the accepted hierarchy of severity of
axon loss among MS subtypes.29
Axonal loss is believed to be a critical mechanism of irre-
versible neurologic disability.30–32 Thus, it was not surprising
that ﬁber fraction, as a surrogate of axon density, correlated
with disability in pwMS (table 1, median of EDSS: RRMS
2.75, PPMS 6, and SPMS 6).
Cognitive impairment aﬀects 40%–70% of pwMS and has
substantial negative consequences.33–35 Although motor
deﬁcits are the principal measures for disease severity scales,36
cognitive impairment is the strongest predictor of work re-
duction or leaving the workforce.37 Previous studies using
DTI also revealed WM tract injury to be strongly associated
with cognitive dysfunction in patients with MS.24,38,39 Focal
abnormalities, particularly in the CC, have been related to
impaired calculation, sequence learning, and memory.24,40–44
It was not unsurprising that abnormal ﬁber fraction and
nonrestricted isotropic fraction correlated best with impaired
cognitive performance in our studies, as they are thought to
reﬂect axonal loss and loss of tissue integrity, respectively.
Previous attempts to correlate DTI metrics with the EDSS
yielded conﬂicting results, with some studies ﬁnding signiﬁ-
cant correlation45–47 and others not.48 We only observed
a correlation between the DBSI and EDSS for the non-
restricted isotropic fraction and only in the SPMS group. We
surmise that the inability to ﬁnd correlations with the EDSS is
due to the dependency of the EDSS on ambulation, and we
expect to see much greater correlations with the EDSS when
in the future we extend DBSI to the spinal cord.
Limitations to our study include that the number of pwMS
enrolled was only 55. The subjects who were enrolled had well-
deﬁned clinical subtypes and were of similar mean ages.
However, our RRMS cohort was older than a typical RRMS
cohort, perhaps resulting in a “benign” group of subjects with
RRMS in this study. Another limitation relates to the TBSS
methodology. TBSS assumes that the eﬀect of interest occurs in
voxels where the local FA is highest and thus may lose sensi-
tivity in detecting pathologic changes in areas of low FA.49
In summary, we used DBSI to assess NAWM integrity within
the CC in RRMS, SPMS, and PPMS cohorts. The DBSI
metric that best indicates axonal loss (ﬁber fraction) reﬂected
the expected hierarchy of axonal loss among clinical subtypes.
Figure 3Graphic illustration of correlation coefficients of clinical test scores with DBSI metrics from the normal-appearing
CC
Graphic illustration of the correlations inMS subjects of clinical test scores (columns)with individualDBSImetrics from the normal-appearing CC (rows) for the
(A) entire CC, (B) genu, (C) body, and (D) splenium. Red circles have a positive correlation, and blue circles have a negative correlation with test scores, with the
size of the circle reflecting the magnitude of the correlation. Data are only shown when the corresponding significant level is p < 0.05, after Benjamini-
Hochberg correction for multiple comparisons. CC = corpus callosum; DBSI = diffusion basis spectrum imaging; Fr = fraction.
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Fiber fraction also correlated with cognitive test results. DBSI
might be useful for quantitatively monitoring the CNS of
individual pwMS, as an outcome measure in clinical trials and
as an aid in recruiting appropriate subjects for future trials of
potential neuroreparative MS therapies.
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